Freshworks to Replace BioLife Solutions in S&P SmallCap 600
S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.
How this was made
The 30-second read
Why it matters
The index addition adds passive demand for Freshworks, while the acquisition creates upside for Repligen and sets a clear valuation for BioLife.
Market read
Three U.S. listed companies are directly affected by index rebalancing and a sizable M&A deal, offering clear trading opportunities.
What to watch
Potential integration risks for Repligen and the cash drain from the $1.5 billion deal.
Background
S&P Dow Jones announced index changes and Repligen disclosed a $1.5 billion acquisition of BioLife, with detailed terms and expected synergies.
Ticker impact
Freshworks will be added to the S&P SmallCap 600 on Oct 8, likely boosting demand from index funds.
likely upward as passive buying commences
Index inclusion drives automatic buying and visibility.
Repligen announced a definitive agreement to acquire BioLife for $1.5 billion, a material M&A transaction.
upward pressure from premium and expected earnings accretion
Deal adds cash and stock consideration, with synergies and EPS accretion.
BioLife is being acquired by Repligen and will be removed from the S&P SmallCap 600.
price will align with deal consideration
Acquisition terms set a clear valuation floor.
Market effects
IT sector gains exposure to Freshworks; biotech/healthcare sees consolidation via Repligen‑BioLife.
U.S. small‑cap indices adjust composition; modest impact on broader market.
Limited to U.S. equity markets; no direct global macro effect.
Counterpoint
If the acquisition faces regulatory delays, RGEN could see short‑term volatility.
Key entities
- CompanyFreshworks Inc.
Software SaaS provider added to S&P SmallCap 600.
- CompanyRepligen Corp.
Biotech firm acquiring BioLife for $1.5 billion.
- CompanyBioLife Solutions Inc.
Target of Repligen acquisition, removed from index.
